Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
3
×
biotech
3
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
3
×
cancer
diagnostics
hepatitis b
merck
microbiome
novartis
pfizer
purdue pharma
vertex pharmaceuticals
abbvie
abeona therapeutics
accent therapeutics
What
drug
3
×
bio
new
roundup
acquisitions
advantages
bar
biggest
brings
build
buy
ceo
cholesterol
company’s
daniel
debut
drugs
dyne’s
expect
expensive
faces
financial
foe
gamble
gilead
healthcare
hint
inhibitors
known
lowering
market
medco’s
microbiome
mover
moves
openly
o’day
patients
payers
pcsk
Language
unset
3
×
Current search:
drug
×
biotech
×
unset
×
" wisconsin top stories "
×
amgen
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)